Beacon Pointe Advisors’s Humacyte HUMA Stock Holding History

Beacon Pointe Advisors’s Portfolio HUMA Stock Details HUMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$28.1K	Hold	36,000	–	–	﹤0.01%	1905
2026 Q1	$21.8K	Hold	36,000	–	–	﹤0.01%	1820
2025 Q4	$34.6K	Hold	36,000	–	–	﹤0.01%	1489
2025 Q3	$62.6K	Hold	36,000	–	–	﹤0.01%	1367
2025 Q2	$75.2K	Buy	36,000 +8,000	+29%	+$15.4K	﹤0.01%	1231
2025 Q1	$47.7K	Buy	28,000 +8,000	+40%	+$30K	﹤0.01%	1200
2024 Q4	$101K	Buy	20,000 +5,000	+33%	+$24.7K	﹤0.01%	1176
2024 Q3	$81.6K	Buy	15,000 +5,000	+50%	+$33K	﹤0.01%	1197
2024 Q2	$48K	Buy	+10,000	New	+$52K	﹤0.01%	1243

Other funds holding HUMA

Antipodes Partners Royal Exchange, Australia $5.46B AUM 26.64% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

DKCM

Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Beacon Pointe Advisors's HUMA Position: Q2 2026 in Review

Beacon Pointe Advisors held its Humacyte (HUMA) position steady in Q2 2026 at 36,000 shares worth $28.1K. The position accounts for ﹤0.01% of the portfolio, ranked #1905.

Beacon Pointe Advisors first reported a position in HUMA in Q2 2024 and has held it in 9 quarters since. The position peaked at $101K in Q4 2024. 161 funds tracked by Wall St. Rank hold HUMA as of Q2 2026.

Beacon Pointe Advisors held 36,000 shares of Humacyte worth $28.1K as of Q2 2026.
Beacon Pointe Advisors left its Humacyte share count unchanged in Q2 2026.
Humacyte made up ﹤0.01% of Beacon Pointe Advisors's portfolio in Q2 2026, its #1905 holding.
Beacon Pointe Advisors first reported a position in Humacyte in Q2 2024 and has held it in 9 quarters since.
Beacon Pointe Advisors's Humacyte position peaked at $101K in Q4 2024.
161 funds tracked by Wall St. Rank held Humacyte as of Q2 2026.

Based on Beacon Pointe Advisors's 13F filing for Q2 2026, filed 18 Aug 2026.